Get free PDF Sample - http://www.researchbeam.com/global-biosimilars-market/request-sample
Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth. The upcoming patent expiration for blockbuster drugs has revolutionized the aspect of commercialization whilst triggering a large scale adoption of biosimilars. Biosimilars industry is facing problems relating to production efficiency and quantity. The lack of economies of scale for small scale manufacturers and absence of regulatory guidelines in lucrative regions such as China, US are hindering the growth of biosimilars market. However, strong government initiatives pertaining to production and approval is a key factor that would eventually reduce the impact of these restraints over the forecast period. Global biosimilars/follow-on-biologics market accounted for an overall revenue of $2,552.0 million in 2014 and it is estimated to generate an approximate revenue of $26,551.3 million by 2020, registering a CAGR of 49.1% from 2015 to 2020.
2016 Global Biosimilars And Follow-On Biologics Industry Report is a professional and in-depth research report on the world’s major regional market conditions of the Biosimilars And Follow-On Biologics industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).
The report firstly introduced the Biosimilars And Follow-On Biologics basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
The report includes six parts, dealing with:
1.) basic information;
2.) the Asia Biosimilars And Follow-On Biologics industry;
3.) the North American Biosimilars And Follow-On Biologics industry;
4.) the European Biosimilars And Follow-On Biologics industry;
5.) market entry and investment feasibility; and
6.) the report conclusion.